RBRichard A. Bernstein

Richard A. Bernstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard A. Bernstein has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Advances in the Detection and Monitoring of Atrial Fibrillation for Patients with Cryptogenic Ischemic Stroke

    by Rajbeer Singh Sangha, Richard Bernstein

    Atrial fibrillation (AF) is a significant etiologic cause of acute ischemic stroke (AIS) that leads to disabling deficits as well as significant morbidity and mortality in this population. Approximately 25 % of AIS is considered to be cryptogenic with no etiology ascertained at the time of the index event. Recent advances from the EMBRACE and CRYSTAL-AF trial have improved detection and treatment of AF and subsequently lead to changes in guidelines. However, with improved detection rates, the duration and frequency cutoffs for treating AF are currently being investigated to ensure optimization of patient selection and subsequent treatment.


  • Detection of Atrial Fibrillation After Cryptogenic Stroke

    by Richard A. Bernstein

    Patients with ischemic stroke and atrial fibrillation (AF) are treated with long-term oral anticoagulation (OAC) because it is considerably more effective than antiplatelet (AP) therapy for the prevention of subsequent strokes and systemic emboli. Therefore, detecting AF changes therapy and makes secondary prevention more effective. Technology for detection of rare episodes of paroxysmal AF (PAF) has improved recently. AF that is only detectable by prolonged monitoring (occult AF, or oAF) may underlie some strokes of unknown cause (cryptogenic stroke). However, the ideal method and duration of cardiac monitoring to detect oAF after stroke is unknown. Furthermore, new technologies allow the detection of brief, rare episodes of AF that would not have been detectable at the time classic studies establishing the benefit of OAC were conducted. Therefore, it is unknown what the minimum threshold of oAF burden or duration is that mandates OAC instead of AP therapy. Here we review the available technologies, and discuss the therapeutic implications and uncertainties when oAF is found after ischemic stroke. There is evidence that 3 weeks of outpatient cardiac telemetry has a high yield of detection of AF after cryptogenic stroke; however, ongoing studies may show that even longer monitoring periods have higher yield.


  • Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis

    by Frances Caprio, Richard A. Bernstein

    Cerebral venous sinus thrombosis (CVST) often occurs in young patients and is treated with acute and then long-term oral anticoagulation. It is important to decide when to discontinue anticoagulation, as lifelong anticoagulation exposes the patient to considerable cumulative risk. However, a lack of high quality studies makes choosing a duration of anticoagulation after CVST difficult. In this article, we review the evidence for different treatment durations in several common clinical scenarios of CVST. In addition, when no direct evidence is available, we discuss and extrapolate from the more comprehensively studied situation of systemic venous thromboembolic disease. Recommendations are graded using standard criteria for the level of evidence.


  • Clinical Diagnosis and Successful Treatment of Inflammatory Cerebral Amyloid Angiopathy

    by Richard A. Bernstein, Michael Gibbs, H. Hunt Batjer

    Cerebral amyloid angiopathy is a major cause of lobar hemorrhage in older adults, and of microvascular ischemic disease. The rarest form of this disease is an inflammatory form causing seizures. It is important to recognize because the patients usually respond to a brief course of immunosuppression. Case report. A 66-year-old man developed gradual cognitive decline, insidiously increasing headaches, and then had a likely seizure. MRI showed diffuse white matter edema, and innumerable superficial microhemorrhages characteristic of amyloid angiopathy. He was empirically treated with oral prednisone and an anticonvulsant. His symptoms improved and the white matter edema resolved over several months. ApoE genotype was 4/4, which is commonly found in inflammatory amyloid angiopathy. Inflammatory cerebral amyloid angiopathy can be clinically diagnosed and treated without brain biopsy. Clinical diagnosis is important because of the good response to a brief course of steroids in most cases.


  • Rupture of Cerebral Myxomatous Aneurysm Months After Resection of the Primary Cardiac Tumor

    by Christopher S. Eddleman, Numa R. Gottardi-Littell, Bernard R. Bendok, H. Hunt Batjer, Richard A. Bernstein

    The natural history of cerebral aneurysms derived from metastatic spread of cardiac myxomas is not well known, and their management presents many dilemmas. Case report and literature review. An 18-year-old man presented with an intraparenchymal hemorrhage several months after resection of an atrial myxoma. Angiography showed several myxomatous aneurysms, one of which had bled. The patient had a recurrent hemorrhage before undergoing surgical resection. MRI, angiographic, and pathological data are presented for this rare condition. Myxomatous aneurysms are important entities for neurointensivists to recognize and can present years after diagnosis. Patients presenting with cerebral infarction or hemorrhage of unknown etiology should undergo cardiac imaging to rule out atrial myxoma, as up to 50% of patients with myxomas present initially with stroke.


  • Prevention of Stroke in Patients with High-Risk Atrial Fibrillation

    by Richard A. Bernstein, Rod Passman

    Atrial fibrillation (AF) causes nearly 10% of all ischemic strokes. Long-term oral anticoagulation with warfarin currently is the best treatment for preventing stroke in patients with AF and other stroke risk factors. However, many eligible patients do not receive warfarin, and some patients with AF are unsuitable for this treatment. Recent clinical trials have tested alternatives to long-term warfarin, and some new treatment options have emerged. Nonpharmacologic approaches to stroke prevention in atrial fibrillation also are under development. In addition, new diagnostic modalities may detect paroxysmal AF with more sensitivity, potentially expanding the population to be treated and the potential impact of stroke preventive strategies on the population. This review provides a practical guide to current treatment and diagnostic options.


  • Response to Letter by Creutzfeldt et al

    by Andrew M. Naidech, Richard A. Bernstein, Bernard R. Bendok, Mark J. Alberts, H. Hunt Batjer


  • Antiplatelet agents for secondary prevention of stroke

    by Richard A. Bernstein

    Patients with recent ischemic stroke or transient ischemic attack (TIA) face a high risk of recurrent stroke as well as an increased risk of myocardial infarction and sudden cardiac death. In the absence of a clearly established indication for long-term anticoagulation, such as atrial fibrillation, antiplatelet agents are the antithrombotic drugs of choice for preventing recurrent vascular events. For many years, aspirin (ASA) has been the first-line therapy for patients at high risk of vascular ischemic events. Two large clinical trials have established the superiority of the combination of ASA and extended-release dipyridamole (ASA/ERDP) over ASA alone in patients with recent noncardioembolic ischemic stroke or TIA. Clopidogrel, another antiplatelet agent, is a reasonable alternative to ASA, but its superiority to ASA in patients with a history of stroke has not been as clearly established. The combination of ASA and clopidogrel, which is effective in patients with acute coronary syndrome, has not been shown to be either effective or safe, compared with either agent alone, in stroke patients, although there may be some benefit to this combination in patients with acute TIA. The results from a large randomized trial comparing ASA/ERDP with clopidogrel, anticipated soon, will further assist clinicians in choosing among available antiplatelet agents.

  • Amplification of Acute Focal Ischemic Deficit by Narcotics

    by Jordan Dubow, Richard A. Bernstein

    This article describes two patients with major ischemic stroke symptoms who had extremely small areas of acute brain infarction, suggestive of acute intrahemispheric diaschisis. Both patients were using narcotic analgesics during their stroke, and in both cases the clinical deficits improved dramatically with naloxone. We postulate that the narcotics amplified the ischemic stroke symptoms and that this effect was antagonized by naloxone. This suggests that the opiate system may be involved in the process of intrahemispheric diaschisis.